AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.

John D. Powderly,Paul de Souza,Rodolfo Gutiérrez,Lisa G. Horvath,Lisa Seitz,Devika Ashok,Adam Park,Matthew J. Walters,Joyson Joseph Karakunnel,Wade Berry,Aimee Rieger,Amanda Garofalo,Dominic W Lai,Arvind Chaudhry

AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.

2019

John D. Powderly
Paul de Souza
Rodolfo Gutiérrez
Lisa G. Horvath
Lisa Seitz
Devika Ashok
Adam Park
Matthew J. Walters
Joyson Joseph Karakunnel
Wade Berry
Aimee Rieger
Amanda Garofalo
Dominic W Lai
Arvind Chaudhry

2604Background: AB928, a selective, small-molecule A2aR/A2bR antagonist, potently blocks the immunosuppressive effects of high adenosine concentrations in the tumor microenvironment. Preclinically,...

Keywords:

Adenosine receptor antagonist
Cancer research
Pathology
Medicine
Chemotherapy
anti pd 1
Tumor microenvironment
in patient
Adenosine
Antagonist

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations